Dopamine agonists and augmentation

Synthesis of the evidence on dopamine agonist (pramipexole, ropinirole, rotigotine), levodopa, and alpha-2-delta ligand (pregabalin, gabapentin, gabapentin enacarbil) treatment for RLS, with a focus on augmentation: its definition, incidence, mechanism, and management. All claims below cite a study note filename (in knowledge-base/studies/) or a PMID. Medical disclaimer: nothing here is individual medical advice; any change to RLS medication, especially tapering a dopamine agonist, must be done only under physician supervision and never stopped abruptly (dopamine agonist withdrawal syndrome, DAWS, can be severe - see 2013-nirenberg-dopamine-agonist-withdrawal-review.md).

What is established (grade A/B)

• Dopamine agonists (pramipexole, ropinirole, rotigotine) and levodopa are efficacious for RLS symptoms in the short term: 12-week fixed-dose pramipexole significantly beat placebo on the IRLS scale (-9.3 placebo vs -12.8/-13.8/-14.0 at 0.25/0.50/0.75 mg/day, all p<0.01; 2006-winkelman-pramipexole-fixed-dose-rct.md), and a Cochrane review of levodopa (9 RCTs, n=521) found significant benefit on symptom severity, PLMS, and quality of life (2011-scholz-cochrane-levodopa-review.md).
• Augmentation is real, dose/drug-dependent, and increases with treatment duration. A 26-week RCT of pramipexole found 9.2% confirmed augmentation by 6 months versus 6.0% on placebo, rising with duration on drug but not on placebo (2011-hogl-pramipexole-6-month-augmentation-rct.md). A 30-week head-to-head RCT found augmentation in 4.0% on cabergoline versus 9.8% on levodopa (p=0.0412) (2007-trenkwalder-cabergoline-levodopa-augmentation.md).
• The pivotal 2014 NEJM trial (n=719) found augmentation over 40-52 weeks in 2.1% on pregabalin versus 7.7% on pramipexole 0.5 mg/day (p=0.001), establishing an alpha-2-delta ligand as lower-augmentation-risk than a dopamine agonist in a single large controlled comparison (2014-allen-nejm-pregabalin-pramipexole-augmentation.md); the companion polysomnographic analysis of the same drug class found pregabalin improved objective sleep continuity at least as well as pramipexole (2014-garcia-borreguero-pregabalin-pramipexole-sleep.md).
• IV iron (ferric carboxymaltose) improves RLS severity: a 2024 meta-analysis of 7 RCTs (537 patients) found a weighted mean IRLS reduction of -6.03 points versus control (p=0.004) (2024-qadri-iv-fcm-meta-analysis.md), consistent with the broader Cochrane iron review (10 trials, 428 patients, IRLS MD -3.78, 95% CI -6.25 to -1.31; 2019-trotti-cochrane-iron-review.md). In one RCT, 37.5% of iron-treated, medication-washed-out patients remained completely RLS-medication-free at 30 weeks (2016-cho-ferric-carboxymaltose-rct-remitters.md).
• Consensus diagnostic criteria for augmentation exist and are stable: the 2003 NIH criteria (2003-allen-nih-consensus-diagnostic-criteria.md) were refined into the 2007 Max Planck Institute (MPI) criteria - earlier symptom onset, more body parts affected, shorter latency to symptoms at rest, greater severity, and shorter drug-effect duration, or a 4+ hour advance in usual onset time (2007-garcia-borreguero-max-planck-augmentation-criteria.md).
• Guideline consensus has shifted decisively away from dopamine agonists as first-line therapy: the 2025 AASM guideline gives only a conditional recommendation against standard pramipexole/ropinirole/rotigotine use (citing augmentation) and strong recommendations for gabapentin, pregabalin, gabapentin enacarbil, and IV ferric carboxymaltose (2025-winkelman-aasm-guideline-rls.md), a marked change from the 2016 AAN guideline, which still rated pramipexole and rotigotine Level A first-line options (2016-winkelman-aan-treatment-guideline.md). The 2026 JAMA clinical review confirms the 7-10%/year augmentation incidence figure and the shift to gabapentinoids-plus-iron as first-line (2026-winkelman-rls-jama-clinical-review.md).

Emerging C

• Real-world (as opposed to trial) augmentation incidence looks similar to or higher than trial estimates: a community survey of 266 dopamine-treated patients found ~8%/year augmentation incidence over the first 8 years of treatment, with 20% meeting definitive/highly-suggestive augmentation criteria and only 25% entirely augmentation-free (2011-allen-community-survey-augmentation-incidence.md).
• Impulse control disorders (ICDs) affect a meaningful minority of dopamine-agonist-treated RLS patients: a German cohort found 7.1% prevalence (10/140) by structured psychiatric interview, most often binge eating, compulsive shopping, and pathological gambling, associated with higher DA dose, younger RLS onset, and family history of gambling disorder (2011-voon-impulse-control-behaviours-cohort.md); a smaller Australian case series (n=12) documented more severe ICD outcomes including criminality and marital breakdown, with impulsivity sometimes persisting after DA withdrawal (2011-dang-impulse-control-disorders-case-series.md).
• Low-dose opioids appear reasonably dose-stable over 2 years as a bridge for patients who have already augmented on dopamine agonists (National RLS Opioid Registry, n=448: median dose change 0 MME over 2 years; 2023-winkelman-national-rls-opioid-registry.md).
• A 2025 Spanish real-world cohort (n=93) of patients with confirmed augmentation found that, despite the diagnosis, 85% remained on a dopamine agonist and only 20% of those had a dose reduction - a large gap between guideline recommendations and routine practice (2025-martin-garcia-spanish-augmentation-cohort.md).

Contested or negative findings

• The Cochrane levodopa review itself flags that augmentation, "the clinically most relevant adverse event," was never adequately studied in the levodopa RCT base (2011-scholz-cochrane-levodopa-review.md) - an explicit evidence gap, not a null result, but one that limits confidence in levodopa's long-term safety despite Grade-A short-term efficacy data.
• Rotigotine was described in 2008 as carrying a "low risk of augmentation" pending further evaluation (2008-baldwin-rotigotine-transdermal-patch-review.md); this claim did not hold up, and the 2025 AASM guideline now recommends against standard rotigotine use for the same augmentation concern that affects oral dopamine agonists (2025-winkelman-aasm-guideline-rls.md).
• The 2024 IV ferric carboxymaltose RCT (n=209) is a genuinely mixed result: IRLS scores improved significantly more with FCM than placebo (-8.0 vs -4.8, p=0.0036) and fewer FCM patients needed rescue RLS medication, but the co-primary Clinical Global Impression response endpoint was not significantly different (35.5% vs 28.7%, p=0.30) - the authors themselves discuss possible methodological problems with the forced-taper design (2024-earley-iv-ferric-carboxymaltose-rct.md). This tempers how strongly an "iron instead of dopamine agonist" strategy can be claimed to work as a stand-alone intervention.
• A single small trial comparing IV iron directly to pramipexole found no significant difference in RLS severity reduction (MD -0.40, 95% CI -5.93 to 5.13, n=30) - too small to be conclusive either way about whether iron alone can substitute for a dopamine agonist (2019-trotti-cochrane-iron-review.md).
• Genetically, RLS risk variants do not map cleanly onto iron-regulatory genes, and the common HFE C282Y hemochromatosis mutation shows no protective effect against RLS - an important negative finding against a purely genetic explanation for brain iron deficiency in RLS (2016-connor-iron-genetics-hypoxia-review.md).

Mechanistic picture in 5 bullet points

• D3-preferring dopamine agonists (pramipexole, rotigotine, ropinirole) initially relieve RLS by inhibiting spinal sensory hyperexcitability via the D3 receptor, but chronic exposure appears to upregulate the oppositely-acting, excitatory D1 receptor; in a mouse model, chronic D3-agonist treatment produced a behavioral switch analogous to augmentation that was reversed by D1-receptor blockade (2017-dinkins-d3-d1-receptor-animal-model.md; mechanism reviewed in 2019-casoni-d3-receptor-agonist-efficacy-review.md, 2023-zeng-augmentation-mechanisms-review.md, and 2025-clemens-d1-d3-receptor-augmentation-model.md, which also ties the D1/D3 imbalance to convergent RLS risk genes MEIS1, BTBD9, MAP2K5, and PTPRD).
• Brain iron insufficiency (shown via CSF, autopsy, and imaging studies) is proposed to drive a presynaptic hyperdopaminergic, circadian-varying state alongside postsynaptic receptor changes, rather than RLS being a simple dopamine-deficiency disorder (2014-earley-iron-dopamine-metabolic-theory-review.md; connectome/PTPRD framing in 2016-earley-connectome-dopamine-augmentation-mechanism.md).
• Cortical and spinal excitability abnormalities in untreated RLS (reduced short-interval intracortical inhibition, absent practice-dependent motor plasticity) are partially normalized by acute-to-short-term dopaminergic treatment (2006-nardone-cabergoline-cortical-hyperexcitability.md, 2010-scalise-dopaminergic-cortical-plasticity.md), suggesting that whatever compensates for these physiological deficits will need to be addressed (pharmacologically or otherwise) during any taper.
• Brain iron dysregulation in RLS does not appear to be directly genetically driven (known RLS risk genes, including HFE, do not explain it), suggesting a functional cellular iron-transport defect rather than a structural or purely inherited one, alongside consistently observed activation of hypoxia-pathway proteins in RLS brain tissue (2016-connor-iron-genetics-hypoxia-review.md).
• Even before formal augmentation criteria are met, prior long-term dopamine agonist exposure measurably impairs subsequent response to both dopaminergic and non-dopaminergic drugs (dipyridamole, suvorexant), implying "subclinical" pathophysiological change precedes clinically visible augmentation (2025-garcia-borreguero-subclinical-augmentation-posthoc.md).

Implications for a non-drug long-term plan for people currently on dopamine agonists or alpha-2-delta ligands

• Never stop a dopamine agonist abruptly. Tapering must be physician-supervised because of dopamine agonist withdrawal syndrome (DAWS) - a severe, dose-dependent symptom cluster (anxiety, panic, dysphoria, suicidal ideation, orthostatic hypotension, drug craving) that is refractory to levodopa and has no proven effective treatment (2013-nirenberg-dopamine-agonist-withdrawal-review.md).
• Check and correct iron status early. Ferritin at or below 75 ng/mL (or transferrin saturation under 20%) should prompt iron repletion per the AASM 2025 guideline (2025-winkelman-aasm-guideline-rls.md); IV ferric carboxymaltose has the strongest trial support (2024-qadri-iv-fcm-meta-analysis.md, 2019-trotti-cochrane-iron-review.md) and, in at least one trial, allowed more than a third of patients to remain medication-free at 30 weeks (2016-cho-ferric-carboxymaltose-rct-remitters.md) - though the 2024 RCT's mixed result (2024-earley-iv-ferric-carboxymaltose-rct.md) means iron alone should not be promised as a guaranteed substitute.
• Prefer switching to (or starting with) an alpha-2-delta ligand (pregabalin, gabapentin, gabapentin enacarbil) over increasing a dopamine agonist dose, per both the pivotal 2014 NEJM trial (2014-allen-nejm-pregabalin-pramipexole-augmentation.md) and the 2016 IRLSSG combined task-force augmentation guideline, which recommends alpha-2-delta ligands specifically to prevent augmentation (2016-garcia-borreguero-augmentation-prevention-treatment-guidelines.md).
• Remove aggravating co-medications (SSRIs/SNRIs, antihistamines, antidopaminergic antiemetics/antipsychotics) as a first step whenever augmentation is suspected, per the same 2016 IRLSSG guideline and the AASM 2025 good-practice statement (2016-garcia-borreguero-augmentation-prevention-treatment-guidelines.md, 2025-winkelman-aasm-guideline-rls.md).
• Screen proactively for impulse control disorders (gambling, compulsive shopping, hypersexuality, binge eating) both before starting and throughout dopamine agonist therapy, independent of the augmentation question, since ICDs affect roughly 7% of dopamine-agonist-treated patients and can persist after stopping the drug (2011-voon-impulse-control-behaviours-cohort.md, 2011-dang-impulse-control-disorders-case-series.md).
• Expect a real-world execution gap. Even after augmentation is correctly diagnosed, most patients in routine practice are not switched off dopamine agonists or even dose-reduced (2025-martin-garcia-spanish-augmentation-cohort.md) - a structured, written, physician-reviewed plan (rather than relying on ad hoc recognition) is likely necessary for this project's protocol to be more effective than usual care.
• Reserve low-dose opioids as a pharmacologic bridge, not a non-drug solution, for the most severe, treatment-resistant augmentation once alpha-2-delta ligands and rotigotine have failed (2016-de-biase-oxycodone-naloxone-intractable-rls.md); real-world dosing appears reasonably stable over 2 years for most patients (2023-winkelman-national-rls-opioid-registry.md).
• Treat emerging non-dopaminergic, non-alpha-2-delta options (D1-receptor antagonists such as ecopipam, NMDA-receptor antagonists such as dextromethorphan) as experimental leads to watch, not as actionable parts of a current protocol (2025-clemens-d1-d3-receptor-augmentation-model.md, 2026-khalil-dextromethorphan-case-report.md, the latter a single case report with no control group).

Open questions

• No prospective, prevention-focused trial has yet tested whether a structured, iron-first, alpha-2-delta-preferred, dopamine-agonist-avoiding strategy actually reduces population-level augmentation incidence, as opposed to the mostly retrospective/cross-sectional and short-RCT data reviewed here.
• There is no proven, validated treatment for DAWS itself once it occurs (2013-nirenberg-dopamine-agonist-withdrawal-review.md); how best to manage it during a supervised taper remains an unresolved clinical problem.
• Whether IV iron can reverse (not just help prevent) established augmentation in patients still on a dopamine agonist is only partially tested; the 2024 RCT's forced-taper design produced a mixed result rather than a clear answer (2024-earley-iv-ferric-carboxymaltose-rct.md).
• The D1/D3 receptor-imbalance model is mechanistically compelling but rests heavily on animal models and a single 10-subject, non-powered human pilot of a D1 antagonist; it has not been tested in a definitive human augmentation trial (2025-clemens-d1-d3-receptor-augmentation-model.md, 2017-dinkins-d3-d1-receptor-animal-model.md).
• The functional (versus genetic) basis of brain iron dysregulation in RLS is still unexplained (2016-connor-iron-genetics-hypoxia-review.md), leaving open why iron repletion helps some patients more than others.
• Long-term (multi-year, ideally 5-10 year) prospective augmentation and de-prescribing outcome data remain sparse; most of the numbers above come from cross-sectional surveys, retrospective cohorts, or RCTs of 6-12 months.

Notes in this topic

Notes authored for this sweep:

• (A note on the 2025 AASM guideline was drafted for this sweep but was a duplicate of the pre-existing 2025-winkelman-aasm-guideline-rls.md, below, and was not kept; corrected 2026-09 quality pass removed two resulting broken references to non-existent filenames.)
• 2016-winkelman-aan-treatment-guideline.md - 2016 AAN guideline still rated pramipexole/rotigotine Level A first-line, showing how far the standard of care has since shifted.
• 2007-garcia-borreguero-max-planck-augmentation-criteria.md - the MPI consensus criteria used to diagnose augmentation.
• 2003-allen-nih-consensus-diagnostic-criteria.md - original NIH RLS diagnostic and augmentation criteria.
• 2016-garcia-borreguero-augmentation-prevention-treatment-guidelines.md - IRLSSG/EURLSSG/RLS-F combined task force: stepwise prevention/treatment algorithm for augmentation.
• 2013-garcia-borreguero-irlssg-long-term-guidelines.md - 2013 IRLSSG long-term treatment evidence grades by drug and duration.
• 2011-hogl-pramipexole-6-month-augmentation-rct.md - RCT: 9.2% augmentation on pramipexole vs 6.0% placebo at 6 months.
• 2011-allen-community-survey-augmentation-incidence.md - real-world survey: ~8%/year augmentation incidence, 20% definitive augmentation.
• 2014-allen-nejm-pregabalin-pramipexole-augmentation.md - pivotal NEJM RCT: 2.1% pregabalin vs 7.7% pramipexole 0.5 mg augmentation.
• 2014-garcia-borreguero-pregabalin-pramipexole-sleep.md - crossover RCT: pregabalin improves sleep continuity at least as well as pramipexole.
• 2023-winkelman-national-rls-opioid-registry.md - 2-year opioid registry: doses mostly stable in augmented/refractory RLS patients.
• 2016-earley-connectome-dopamine-augmentation-mechanism.md - PTPRD/receptor-interaction hypothesis for augmentation.
• 2017-dinkins-d3-d1-receptor-animal-model.md - mouse model: chronic D3-agonist behavioral switch reversed by D1 blockade.
• 2008-baldwin-rotigotine-transdermal-patch-review.md - early (2008) rotigotine review; its "low risk of augmentation" claim has since been superseded.
• 2015-trenkwalder-rls-therapies-augmentation-review.md - review noting very little controlled data exist on managing established augmentation.
• 2019-casoni-d3-receptor-agonist-efficacy-review.md - D3-receptor pharmacology review linking D1 activation to augmentation.
• 2016-de-biase-oxycodone-naloxone-intractable-rls.md - opioid option for the most severe, refractory augmentation.
• 2011-dang-impulse-control-disorders-case-series.md - 12-case series of severe impulse control disorders on dopamine agonists.
• 2013-nirenberg-dopamine-agonist-withdrawal-review.md - DAWS definition, risk factors, and the absence of a proven treatment.
• 2018-wang-acute-drug-withdrawal-rls-symptoms.md - objective (PSG/EMG) study of acute withdrawal from pramipexole, gabapentin, and oxycodone (abstract unavailable; see note for details).
• 2006-winkelman-pramipexole-fixed-dose-rct.md - 12-week fixed-dose pramipexole RCT establishing short-term efficacy.
• 2011-scholz-cochrane-levodopa-review.md - Cochrane review: levodopa efficacious, augmentation under-studied.
• 2019-trotti-cochrane-iron-review.md - Cochrane review: iron beats placebo; single small trial vs pramipexole inconclusive.
• 2014-earley-iron-dopamine-metabolic-theory-review.md - iron-deficiency-dopamine mechanistic theory review.
• 2016-connor-iron-genetics-hypoxia-review.md - negative finding: RLS genes/HFE do not explain brain iron deficiency.
• 2007-paulus-pathophysiology-update-genetics.md - early (2007) review of RLS neuroanatomy and genetics (MEIS1, BTBD9, MAP2K5/SKOR1).
• 2024-earley-iv-ferric-carboxymaltose-rct.md - 2024 RCT of IV iron with medication taper; mixed (mostly positive but not fully conclusive) result.
• 2024-qadri-iv-fcm-meta-analysis.md - 2024 meta-analysis (7 RCTs, 537 patients) confirming IV FCM efficacy.
• 2016-cho-ferric-carboxymaltose-rct-remitters.md - IV iron RCT: 37.5% medication-free at 30 weeks.
• 2011-voon-impulse-control-behaviours-cohort.md - cohort: 7.1% impulse control behavior prevalence on dopaminergic therapy.
• 2025-martin-garcia-spanish-augmentation-cohort.md - 2025 real-world cohort: most augmented patients stay on dopamine agonists despite guidelines.
• 2025-garcia-borreguero-subclinical-augmentation-posthoc.md - post hoc RCT analysis: subclinical pathophysiological change precedes formal augmentation.

Pre-existing notes found in the knowledge base (written by other project agents), also relevant to this topic:

• 2025-winkelman-aasm-guideline-rls.md - the 2025 AASM clinical practice guideline (PMID 39324694).
• 2006-nardone-cabergoline-cortical-hyperexcitability.md - cabergoline reverses cortical disinhibition in RLS (TMS study).
• 2007-trenkwalder-cabergoline-levodopa-augmentation.md - 30-week RCT: augmentation 4.0% cabergoline vs 9.8% levodopa.
• 2010-scalise-dopaminergic-cortical-plasticity.md - dopaminergic treatment partially restores practice-dependent cortical plasticity.
• 2023-zeng-augmentation-mechanisms-review.md - review citing augmentation rates rising from ~10% short-term to 42-68% over roughly 10 years of dopaminergic treatment.
• 2025-clemens-d1-d3-receptor-augmentation-model.md - integrative D1/D3 receptor-imbalance model of augmentation, including a small ecopipam (D1-antagonist) pilot.
• 2026-khalil-dextromethorphan-case-report.md - single case report of an NMDA antagonist relieving dopamine-agonist-refractory RLS.
• 2026-winkelman-rls-jama-clinical-review.md - 2026 JAMA review confirming the 7-10%/year augmentation figure and the shift to gabapentinoids-plus-iron as first-line care.

Additional linked notes (2026-09 quality pass)

These notes carry this topic tag but are not yet woven into the prose synthesis above; listed here so they are discoverable and counted in catalog.json rather than orphaned.

• 2011-bayard-dopamine-dysregulation-rls-parkinson.md (2011) - [Dopamine dysregulation syndrome in Parkinson's disease and restless legs syndrome]: A French review from the Montpellier sleep-disorders unit (Hopital Gui-de-Chauliac, Dauvilliers' group) on dopamine dysregulation syndrome (DDS) - impulsive/compulsive behaviours such as pathological gambling, hyperse...
• 2011-inoue-gabapentin-enacarbil-longterm-japan.md (2011) - Long-term efficacy and safety of gabapentin enacarbil in Japanese restless legs syndrome patients: A 52-week multicenter open-label study of gabapentin enacarbil (GEn) 1200 mg/day in Japanese RLS patients found sustained, large symptom improvement and no reported episodes of augmentation over the full year.
• 2011-moskovko-elderly-rls-underdiagnosed-review.md (2011) - Syndrom nespokiynykh nih v osib starshoho ta pokhyloho viku: nedootsinenyi ta nedolikovanyi 'tinovyi' fenomen (Restless legs syndrome in the elderly: an underestimated and undertreated 'shadow' phenomenon): A Ukrainian academic review (Vinnytsia National Pirogov Memorial Medical University) argues RLS in older adults is systematically under-recognized because patients present with nonspecific sleep complaints rather than...
• 2013-nagandla-pathophysiology-modern-management-review.md (2013) - Restless legs syndrome: pathophysiology and modern management: This narrative review, authored from Melaka Manipal Medical College, Malaysia, summarizes RLS pathophysiology (dopaminergic dysfunction, reduced CNS iron, genetic linkage, hypocretin/endorphin/immune mechanisms) and c...
• 2015-narowska-augmentation-ropinirole-case-report.md (2015) - Frequent difficulties in the treatment of restless legs syndrome - case report and literature review: This case report from the Institute of Psychiatry and Neurology (IPiN) in Warsaw documents augmentation during long-term ropinirole therapy, managed by gradual dopaminergic withdrawal and transition to gabapentin as s...
• 2017-yachnik-aan-guideline-translation-ukraine.md (2017) - Kerivnytstvo z likuvannya syndromu nespokiynykh nih u doroslykh (Guideline for the treatment of restless legs syndrome in adults; Ukrainian-language summary of the AAN 2016 subcommittee report): This is a Ukrainian-language digest, prepared for local clinicians, of the American Academy of Neurology (AAN) 2016 practice guideline on RLS management, making AAN-graded recommendations accessible in Ukrainian befor...
• 2019-sieminski-metoclopramide-induced-rls-case-report.md (2019) - Acute Drug-Induced Symptoms of Restless Legs Syndrome in an Emergency Department: This Gdansk emergency-department case report describes acute-onset RLS symptoms triggered by intravenous metoclopramide (a dopamine D2-receptor antagonist antiemetic) given during migraine treatment, with symptoms res...
• 2020-akhmadulina-levin-rls-parkinsons-review.md (2020) - Restless legs syndrome in Parkinson's disease: This review by Levin's group at the Russian Medical Academy of Continuous Professional Education (Moscow) evaluates three competing hypotheses for the well-documented association between RLS and Parkinson's disease (P...
• 2020-bartl-update-restless-legs-syndrom.md (2020) - [Update on restless legs syndrome]: A narrative update for German neurologists (Der Nervenarzt) from the Paracelsus-Elena Klinik Kassel/Gottingen group (Trenkwalder's team), summarising RLS diagnosis, drug options and the augmentation problem for clinic...
• 2021-moderie-sleep-disorders-neurocognitive-quebec.md (2021) - [Sleep disorders in patients with a neurocognitive disorder]: A French-language narrative review from Quebec (Universite de Montreal / Concordia University, Dang-Vu's group) on sleep disorders in neurocognitive disorders gives specific, practical RLS guidance for a frail/elderly...
• 2021-vlasie-rls-pathophysiology-review.md (2021) - Restless legs syndrome: An overview of pathophysiology, comorbidities and therapeutic approaches: This Bucharest-authored narrative review (Department of Psychiatry, "Prof. Dr. Alexandru Obregia" Clinical Hospital, and "Carol Davila" University of Medicine and Pharmacy) summarizes RLS pathophysiology, comorbiditie...
• 2022-das-olanzapine-induced-rls-case.md (2022) - Olanzapine-induced restless leg syndrome (Willis-Ekbom disease): A case report: A single case report describes new-onset RLS (Willis-Ekbom disease) attributed to olanzapine, a second-generation antipsychotic, in a woman being treated for bipolar affective disorder; symptoms were managed by adding...
• 2022-heidbreder-dgn-s2k-leitlinie-rls.md (2022) - Restless Legs Syndrom, S2k-Leitlinie: The German S2k guideline (Deutsche Gesellschaft fur Neurologie/DGN with DGSM, plus Austrian and Swiss neurology/sleep societies; RLS e.V. patient organisation on the panel), version 5.0, valid to 24.06.2027, sets Germ...
• 2022-khachatryan-european-contribution-review.md (2022) - Restless legs syndrome: Over 50 years of European contribution: This narrative review, co-authored by Italian sleep researcher Raffaele Ferri (Oasi Research Institute-IRCCS, Troina) and Italian/Swiss researcher Mauro Manconi, traces RLS from Thomas Willis (17th century) and Karl-A...
• 2026-srikajon-underrecognized-rls-parkinsons-thai.md (2026) - Underrecognized restless legs syndrome in Parkinson's disease: Diagnostic delay, association with sleep burden, and dopaminergic exposure in a Thai cohort: In a Thai cross-sectional cohort of 250 PD patients (ClinicalTrials.gov NCT06684782), 23.2% (95% CI 18.4–28.8) met RLS criteria, but 95.8% of these cases had never been previously diagnosed, with a mean diagnostic del...